BridgeBio Pharma, Inc. BBIO
As ofNov 17, 2026, 3:23 PM EST
- YTD
- +0.26%
- 1 year
- +14.63%
BBIO free cash flow history
Free cash flow is operating cash flow minus capital expenditure outflow. It can be negative; it is not the same as earnings.
-447,007,000 USD
FY 2025 · Period ended
Coverage: incomplete. Values in USD; not inflation adjusted.
Capital expenditure is reported net of asset sales as an inflow for some periods; free cash flow is not shown for them.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Capital expenditure here is net of asset disposals, so free cash flow can be higher than a figure that subtracts gross purchases.
Missing observations.
Scroll the table to see all values →
| Fiscal period | Period end | Free cash flow | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | -447,007,000 | 74,652,000 | Not meaningful |
| FY 2024 | 2024-12-31 | -521,659,000 | 7,367,000 | Not meaningful |
| FY 2023 | 2023-12-31 | -529,026,000 | Not available | Not available |
| FY 2022 | 2022-12-31 | Not available | Not available | Not available |
| FY 2021 | 2021-12-31 | -511,180,000 | -103,948,000 | Not meaningful |
| FY 2020 | 2020-12-31 | -407,232,000 | -151,007,000 | Not meaningful |
| FY 2019 | 2019-12-31 | -256,225,000 | -117,404,000 | Not meaningful |
| FY 2018 | 2018-12-31 | -138,821,000 | -97,869,000 | Not meaningful |
| FY 2017 | 2017-12-31 | -40,952,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-05-08T14:24:23.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.
